Leiva Andrea, Contreras-Duarte Susana, Amigo Ludwig, Sepúlveda Esteban, Boric Mauricio, Quiñones Verónica, Busso Dolores, Rigotti Attilio
Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics and Gynaecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
PLoS One. 2017 Sep 14;12(9):e0184280. doi: 10.1371/journal.pone.0184280. eCollection 2017.
For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic-diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61h/h) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population.
为实现正常的胆固醇代谢,需要清道夫受体B类I型(SR-BI)正常表达并发挥功能,SR-BI是一种高密度脂蛋白(HDL)受体。在调节整体胆固醇稳态和HDL代谢的诸多因素中,核法尼醇X受体发挥着重要作用。古古甾酮是天然产物古古脂中含有的一种生物活性化合物,是该受体的拮抗剂。这种天然产物在全球被广泛用作天然降脂剂,但其在动物模型或人类中的抗动脉粥样硬化心血管益处尚不清楚。本研究的目的是确定古古脂对雄性小鼠胆固醇稳态以及轻度和重度动脉粥样硬化发展的影响。为此,我们评估了古古脂治疗对野生型小鼠肝脏组织学、血浆脂蛋白胆固醇、内皮功能以及动脉粥样硬化和/或缺血性心脏病发展的影响;载脂蛋白E基因敲除小鼠,一种无缺血并发症的动脉粥样硬化模型;以及SR-BI基因敲除和高脂饮食喂养的载脂蛋白E低表达(SR-BI KO/ApoER61h/h)小鼠,一种因严重动脉粥样硬化导致致命性缺血性心脏病的模型。给予古古脂与肝脏组织学异常、丙氨酸转氨酶水平升高、肝脏SR-BI含量降低、因HDL胆固醇水平升高导致的高胆固醇血症、内皮功能障碍、动脉粥样硬化加重以及严重缺血性心脏病动物死亡加速有关。总之,我们的数据显示摄入古古脂对雄性小鼠的HDL代谢和动脉粥样硬化有重要不良影响,提示对人类心血管健康可能存在未知的有害影响。此外,这些发现再次强调需要进行严格的临床前和临床研究,为天然产物的消费及其在普通人群中的使用监管提供指导。